Remsima, an anti-TNF-alpha monosomal subcutaneous formulation, was approved and the treatment time was reduced to 25 minutes.

The European Commission approved Remsima, the world's first subcutaneous formulation of infliximab, for five other indications, including aggressive spina bifida (AS), Crohn's disease (CD), ulcerative colitis (UC), psoriasis arthritis (PsA) and psoriasis (PsopsyPstoclias).
photo source: Inphyseiamisis is a human rat chimeric monotortagain against the tumor necrosis factor (TNF-alpha), a subcutaneous preparation that can be administered by the patient himself, reducing the treatment time to about twenty-five minutes, and the efficacy and safety of the drug's intravenous formulation.
approval was made in June after receiving confirmation from the European Medicines Agency's Human Drug Commission, based on data from a key study that compared the pharmacodynamics, efficacy and safety parameters of Remsima's subcutaneous and intravenous preparations for one year in patients with active Crohn's disease and ulcerative colitis.
picture source: Abstracts of the 15th Of ECCO - European Crohn's and Colitis German Professor Stefan Schreiber said: "Remsima's approval marks an important development in the field of gastroenterology, which means that patients can be treated in less time, providing greater flexibility and changing the way treatment is treated.
"